Markets open

Danaher Corporation

DHR · NYSE

Analyst Consensus

Buy

21 analysts

$229

Current

—

Low

$260

Average

—

High

Average target implies +13.54% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Buy across 21 analysts, with a mean target of $260. Other aggregates place the average near $260–$270: Investing.com reports $259.90, while Zacks reports $269.55; the stated ranges extend from $220 to $310, and MarketBeat’s target is $242.91. The evidence does not identify the most or least bullish individual analyst. It also does not establish a direction for sell-side revisions during this week: Baird raised its target to $254 from $246 after Q3 results, while Simply Wall St describes a recent series of mostly downward target changes. The substantive disagreement is over growth, profitability and valuation assumptions.

Rating Actions

No individual rating actions have been captured for DHR yet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

CITIGROUP

DEUTSCHE BK SEC

EDWARD JONES

GOLDMAN SACHS

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

KEYBANC CAP MKT

LEERINK PARTNRS

RAYMOND JAMES

RBC CAPITAL

STIFEL NICOLAUS

STONEX FINANCIA

TD COWEN

UBS

WILLIAM BLAIR

WOLFE RESEARCH

ZACKS RESEARCH

Symbol: DHR
Type: Stock
Sector: Industrials
Industry: Industrial Machinery/Components
Country: North America
Exchange: NYSE

Danaher is a leading global life sciences, diagnostics and biotechnology innovator committed to advancing the power of science and technology to improve human health. Through a connected ecosystem of industry-leading businesses, the Company works closely with customers to solve many of their most complex scientific challenges by accelerating discovery, development and the delivery of life-changing therapies. Powered by the Danaher Business System and 60,000 associates worldwide, the Company strives for continuous improvement, operational excellence and Innovation at the Speed of Life.

Key Issues

Bullish view

Zacks upgraded Danaher to Rank #2 (Buy), citing growing optimism about its earnings prospects.

Bearish view

Simply Wall St says analysts lowered their target by about $8 to roughly $250 as they adopted more conservative growth, profitability and valuation assumptions.

Analyst Consensus

See all

Buy

21 analysts

$229

Current

—

Low

$260

Average

—

High

Average target implies +13.54% versus the current price.

Earnings History

BeatMissNo estimate

Danaher Corporation

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers